Key result
Serum S-100B shows no difference versus healthy controls as a neuronal damage marker in SSPE.
Why the study?
S-100B is a peripheral biomarker for blood-brain barrier disruption and neuronal damage, but its levels in patients with subacute sclerosing panencephalitis were not investigated.
Are serum S-100B levels elevated in children with subacute sclerosing panencephalitis compared to healthy controls?
Case-Control (n=80)
No
Are serum S-100B levels elevated in children with subacute sclerosing panencephalitis compared to healthy controls?
Serum S-100B is not a reliable peripheral biomarker for neuronal damage in children with subacute sclerosing panencephalitis.
Serum S-100B was not elevated in SSPE versus controls; leaves open its role as a neuronal damage marker and requires larger prospective validation.
Objectives: S-100B a protein prevalent in the central nervous system is a peripheral biomarker for blood-brain barrier disruption and neuronal damage. The objective of the study was to investigate the S-100B levels in patients with subacute sclerosing panencephalitis. Materials and methods: A group of 40 patients with SSPE and 40 healthy controls were recruited. Serum S-100B protein concentrations were measured using a commercially available electrochemiluminescence immunoassay (ECLIA) kit, as supplied and according to the manufacturer's standards. Results: Median S-100B levels were 0.095 ± 0.017 μg/L in patients with SSPE and 0.097±0.019 μg/L in the control group. This difference was not statistically significant (p>0.05). The patient group was further subdivided into two subgroups according to the presence or absence of brain atrophy. The S-100B levels were 0.096 ± 0.018 μg/L in the subgroup with atrophy and 0.094±0.014 μg/L in the subgroup without atrophy. This difference was also not statistically significant (p>0.05). Conclusions: Our results suggest that serum S-100B is not a reliable marker for neuronal damage in SSPE.
No takes yet. Share an insight, caveat, or question.
Çalık et al. (2012) conducted a case-control in Subacute Sclerosing Panencephalitis (n=80). Subacute Sclerosing Panencephalitis vs. Healthy controls was evaluated on Serum S-100B protein concentration (μg/L) (p=0.692). Serum S-100B levels did not significantly differ between children with subacute sclerosing panencephalitis and healthy controls (0.095 vs 0.097 μg/L, p=0.692), suggesting it is not a reliable peripheral marker for neuronal damage in SSPE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: